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STRATEGIES FOR INTERRUPTING PROGRESSIVE RENAL DISEASE
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The hyperfiltration theory: A paradigm shift in nephrology. Experimen-
tal studies incriminate glomerular hypertension in mediating progressive
renal damage after any of a variety of initiating injuries. Prevention of
glomerular hypertension by dietary protein restriction or antihypertensive
therapy lessens progressive glomerular damage in several experimental
models of chronic renal disease. Glomerular hypertension and hyperfil-
tration also occur in humans with diabetes mellitus, solitary or remnant
kidneys, and various forms of acquired renal disease. Clinical studies
indicate that dietary protein restriction and antihypertensive therapy also
slow progression in many of these disorders. Large multicenter trials
confirm the beneficial effects of these therapeutic maneuvers on the rate
of progression of chronic renal disease.
Chronic renal insufficiency in humans usually progresses to
end-stage renal failure. A decade ago, on the basis of studies in
animals, Brenner and colleagues proposed that maladaptive gb-
merular hemodynamic changes exert a major influence on the
factors that initiate and perpetuate disease progression [1, 2].
These hemodynamic changes lead to glomerular hyperfiltration,
an adaptation seen in response to a reduction in functional
nephron number whether induced genetically, surgically, or by
acquired renal disease. The elevated single nephron glomerular
filtration rate (SNGFR) common to these pathophysiologic con-
ditions is usually caused by increases in the glomerular capillary
plasma flow rate (QA) and mean glomerular capillary hydraulic
pressure (P), which in turn are due to adaptive reductions in
pregbomerular and postglomerular arteriolar resistances.
Progressive glomerular sclerosis and proteinuria eventually
occur in most experimental models of renal disease characterized
by glomerular hyperfiltration and hypertension. Systemic hyper-
tension often is also present, as in extreme renal ablation [21,
bilateral renal infarction [3], post-salt hypertension [3, 4], two-
kidney one-clip Goldblatt hypertension [51, desoxycorticosterone
(DOCA)-salt hypertension [61, and the Fawn-hooded rat [7], a
strain congenitally predisposed to chronic renal failure. Systemic
hypertension is not required for glomerular capillary hyperfiltra-
tion and hypertension; however, since in diabetic rats an acquired
reduction in afferent arteriolar resistance (RA) not only increases
QA but allows a greater fraction of the systemic blood pressure to
be transmitted into the glomerular capillary network, thereby
raising P despite normal renal perfusion pressure.
Prevention of glomerular hypertension leads to less
glomerular injury
Amelioration of glomerular capillary hyperfiltration and hyper-
tension by therapeutic maneuvers invariably lessens renal injury.
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For example, dietary protein restriction limits the adaptive in-
creases in SNGFR and P€ that occur in various models of
experimental renal disease [1, 2, 6, 8—121. Systemic blood pressure
usually fails to decline with protein restriction, yet glomerular
injury is consistently ameliorated compared with control animals
on normal [6, 8—10] or high [6, 8, 10] protein diets, again
highlighting the importance of glomerular rather than systemic
hypertension in subsequent glomerular injury. Dietary protein
restriction also preserves renal function and limits structural
injury even when instituted in the setting of established renal
injury [10], a finding of obvious relevance to the management of
human renal disease.
Antihypertensive drugs also slow the progression of experimen-
tal renal disease, Here again the importance of single nephron
rather than systemic hemodynamics is evident in that agents which
lower systemic blood pressure without correcting glomerular
hypertension do not usually ameliorate glomerular injury. Studies
have also revealed that glomerular capillary hypertension, rather
than hyperperfusion or hyperfiltration, is in fact the most critical
determinant of gbomerular injury. Anderson et a! [13, 14] and
Lafayette et a! [15] treated partially nephrectomized rats with
either the angiotensin-converting enzyme (ACE) inhibitor enala-
pril or with "triple therapy," a combination of reserpine, hydral-
azine, and hydrochlorothiazide. Both approaches ameliorated
systemic hypertension, although triple therapy, having little or no
beneficial effect on glomerular flows and pressures, did not
protect against glomerular injury. Enalapril, on the other hand,
preserved normal gbomerular capillary pressure and ameliorated
proteinuria and glomeruloscierosis, despite persistence of gbomer-
ular capillary hyperperfusion and hyperfiltration. An angiotensin
II receptor antagonist afforded the same protective effect as
enalapril [15]. Other investigators using other experimental mod-
els as well as other therapeutic maneuvers to reduce P0 have
obtained similar results [16—18]. Thus, when glomerular capillary
hypertension is controlled, glomerular injury is prevented or
greatly reduced.
Nonhemodynamic processes may also contribute to the pro-
gression of chronic renal disease. Thus, lipid-lowering agents [19],
heparin [20], and dietary sodium restriction [21, 22] limit glomer-
ular injury without controlling gbomerular capillary hypertension
in the uninephrectomized spontaneously hypertensive rat (SHR)
and in rats with subtotal nephrectomy, presumably by limiting
gbomerular lipid deposition, intravascular thrombosis, compensa-
tory growth, or capillary wall tension. Vasoactive substances
themselves also may have effects on clotting and cell growth, and
thus might contribute to progression through both hemodynamic
and nonhemodynamic pathways.
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Role of altered glomerular hemodynamics in humans
The influence of hyperfiltration, the most readily monitored
surrogate of altered glomerular hemodynamics, on renal function
in humans has been most thoroughly evaluated in kidney trans-
plant donors and in patients uninephrectomized for acquired
renal disease. Even after one to two decades, total GFR often
averages approximately 70% of prenephrectomy values despite
the 50% reduction in renal mass, indicating that the remaining
kidney is indeed hyperfiltering. Most studies have shown that in
association with this hyperfiltration the prevalence of hyperten-
sion in both groups tends to increase after uninephrectomy,
although only in transplant donors is hypertension apt to be more
prevalent than in local, control populations. Similarly, the preva-
lence of proteinuria tends to increase in both groups after
uninephrectomy, and in one study of patients uninephrectomized
for renal disease [23], proteinuria was shown to increase as a
function of time after surgery as well. However, most investigators
have not been able to demonstrate that blood pressure, protein-
uria, or GFR correlate in any way with time since uninephrec-
tomy, or with each other. Many conclude that because values for
GFR remain relatively stable over time, hyperfiltration in these
uninephrectomized adults does not adversely affect the remaining
kidney. This conclusion seems premature, however, as the mean
duration of follow-up in these patients is usually less than two
decades [24]. Experimental data clearly show that although renal
insufficiency develops very gradually in uninephrectomized ani-
mals, it eventuates much earlier than in two-kidney control
subjects [25]. It is therefore crucial that renal function in these
individuals be followed for several decades before conclusions
regarding long-term safety are reached. Patients with unilateral
renal agenesis differ from uninephrectomized adults in that they
hyperfilter from birth. After approximately three decades of
hyperfiltration they may develop proteinuria, sometimes but not
always in association with the development of hypertension and
renal insufficiency. Nevertheless, patients with this disorder who
undergo biopsy for proteinuria invariably exhibit the lesions of
focal and segmental glomerular sclerosis [26—29], the same lesion
that develops experimentally in the setting of reduced renal mass.
Interestingly, this is also true of patients uninephrectomized for
unilateral disease who subsequently undergo biopsy for protein-
uria [26—33]. Thus, while it is true that most people with unilateral
agenesis do not develop progressive renal disease, it is reasonable
to infer that at least in some, longstanding hyperfiltration may
contribute to the development of renal injury.
Several reports have examined the development of renal injury
in patients who have undergone a greater than 50% reduction in
total renal mass [34—38]. Thirty-six of the reported patients were
followed for an average of 12 years, and of these, 30% developed
systemic hypertension de novo or required antihypertensive med-
ications to control their blood pressure. A striking 70% of patients
in whom 24-hour urinary excretion rates were measured [36—38]
developed significant proteinuria. Novick et a! [38] demonstrated
that, just as in rats with subtotal nephrectomy, the extent of
proteinuria correlated directly with the duration of follow-up and
inversely with the amount of renal tissue remaining. Furthermore,
in four of five patients undergoing biopsy for moderate to severe
proteinuria [36, 38, 39] the pathologic lesion found was focal and
segmental glomerulosclerosis. Thus, with respect to the develop-
ment of hypertension, proteinuria, and glomerulosclerosis, the
human model of extensive renal ablation accurately resembles its
experimental counterpart. Significantly, two of the three patients
followed the longest by Novick et al [38] developed end-stage
renal disease requiring hemodialysis, suggesting that subtotal
nephrectomy in humans may indeed lead to renal insufficiency as
well. The theory that solitary kidneys given in the course of renal
transplantation ultimately fail due at least in part to nonimmuno-
logic (hemodynamic) factors has recently been postulated (see
[40] for a detailed discussion of this issue).
Hyperfiltration occurs in certain pathophysiologic conditions
even when renal mass is intact, as in diabetes mellitus [41, 42]. It
has been shown that hyperfiltration predicts the subsequent
development of nephropathy in patients with type I diabetes
[43—45], independently of the degree of metabolic control.
Therapeutic options in human renal disease
Therapies shown to limit glomerular hyperfunction and to
ameliorate renal injury in animals have begun to be tested in
humans. Dietary protein restriction and antihypertensive drug
therapy [46] have been the principal therapeutic interventions
tested thus far. A recent meta-analysis of studies of low-protein
diets in renal insufficiency, based only on data from prospective
randomized, controlled trials in nondiabetic patients, suggests
that dietary protein restriction indeed delays the onset of end-
stage renal disease. Evidence also suggests that dietary protein
restriction retards the progression of diabetic renal disease as well
[47]. The Modification of Diet in Renal Disease Study, a large
multicenter clinical trial, also demonstrates a benefit of dietary
protein restriction and aggressive reduction in blood pressure on
the rate of progression of chronic renal disease in humans with
significant proteinuria and baseline ongoing deterioration of renal
function [48]. ACE inhibitors have also been shown to offer
protection in non-diabetic chronic renal failure [49].
Among diabetics, randomized multicenter clinical trials have
examined the merits of ACE inhibitors in both Type I and Type II
patients. Evidience in support of a strong renoprotective effect of
this class of antihypertensive therapy was obtained in those with
already overt nephropathy as well as in those with incipient
nephropathy [50—53]. Based on these findings various profes-
sional organizations have issued formal guidelines enthusiastically
supporting ACE inhibitors in diabetic subjects.
Conclusions
The history of our thinking about the inexorable progression of
renal disease involves nearly a half-decade of discontinuity after
the work of Addis [54]. Interest in this area was reawakened by the
paper of Hostetter et al [2] and the essay by Brenner, Meyer, and
Hostetter [1]. Since then, clinicians are no longer content with
merely anticipating progressive loss of renal function in patients
with congenital and acquired forms of chronic renal disease, but
have begun instead to design, test and implement various dietary
and pharmacologic interventions aimed at improved control of
blood pressure (a now highly appreciated cause of accelerated
progression) and particularly glomerular pressure. This paradigm
shift is already deemed responsible for reducing the cumulative
incidence of nephropathy in diabetic patients [55] and is antici-
pated to impact favorably on other forms of chronic renal disease
as well.
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